Evidence map›Paper›PMID 36657991›Full record

ArticleNeurology2023

Dysphagia and Lung Disease in Children With Spinal Muscular Atrophy Treated With Disease-Modifying Agents.

Archana Chacko, Jeanne Marshall, Olivia Taylor, Jane McEniery, Peter D Sly, Leanne M Gauld

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Classifying neurogenic dysphagia as a movement disorder.Brain : a journal of neurology · 2025
    Review
  4. Article
  5. Swallowing function in patients with spinal muscular atrophy before and after the introduction of new gene-based therapies: what has changed?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  6. Fiberoptic endoscopic evaluation of swallowing (FEES) in children with spinal muscular atrophy type 1: feasibility, swallowing safety and efficacy, and dysphagia phenotype.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Archana ChackoFrom the Centre for Child Health Research (A.C., P.D.S., L.M.G.), University of Queensland; Queensland Respiratory and Sleep Department (A.C., L.M.G.); Speech Pathology Department (J. Marshall, O.T.), Queensland Children's Hospital; School of Health and Rehabilitation Sciences (J. Marshall), The University of Queensland; Radiology Department (J. McEniery), Queensland Children's Hospital, Brisbane, Australia. archana.bodapati@hotmail.com.
Jeanne MarshallFrom the Centre for Child Health Research (A.C., P.D.S., L.M.G.), University of Queensland; Queensland Respiratory and Sleep Department (A.C., L.M.G.); Speech Pathology Department (J. Marshall, O.T.), Queensland Children's Hospital; School of Health and Rehabilitation Sciences (J. Marshall), The University of Queensland; Radiology Department (J. McEniery), Queensland Children's Hospital, Brisbane, Australia.
Olivia TaylorFrom the Centre for Child Health Research (A.C., P.D.S., L.M.G.), University of Queensland; Queensland Respiratory and Sleep Department (A.C., L.M.G.); Speech Pathology Department (J. Marshall, O.T.), Queensland Children's Hospital; School of Health and Rehabilitation Sciences (J. Marshall), The University of Queensland; Radiology Department (J. McEniery), Queensland Children's Hospital, Brisbane, Australia.
Jane McEnieryFrom the Centre for Child Health Research (A.C., P.D.S., L.M.G.), University of Queensland; Queensland Respiratory and Sleep Department (A.C., L.M.G.); Speech Pathology Department (J. Marshall, O.T.), Queensland Children's Hospital; School of Health and Rehabilitation Sciences (J. Marshall), The University of Queensland; Radiology Department (J. McEniery), Queensland Children's Hospital, Brisbane, Australia.
Peter D SlyFrom the Centre for Child Health Research (A.C., P.D.S., L.M.G.), University of Queensland; Queensland Respiratory and Sleep Department (A.C., L.M.G.); Speech Pathology Department (J. Marshall, O.T.), Queensland Children's Hospital; School of Health and Rehabilitation Sciences (J. Marshall), The University of Queensland; Radiology Department (J. McEniery), Queensland Children's Hospital, Brisbane, Australia.
Leanne M GauldFrom the Centre for Child Health Research (A.C., P.D.S., L.M.G.), University of Queensland; Queensland Respiratory and Sleep Department (A.C., L.M.G.); Speech Pathology Department (J. Marshall, O.T.), Queensland Children's Hospital; School of Health and Rehabilitation Sciences (J. Marshall), The University of Queensland; Radiology Department (J. McEniery), Queensland Children's Hospital, Brisbane, Australia.
University of Queensland · AUQueensland Children’s Hospital · AURespiratory Clinical Trials · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDisease-modifying agents (DMAs) for the treatment of spinal muscular atrophy (SMA) have evolved the SMA phenotype with improved survival. Ongoing oropharyngeal dysphagia and respiratory complications are reported. The extent of dysphagia and respiratory morbidity in this population, since DMAs' introduction, has not been well described.

methodsA whole-population study involved all children with treated SMA types 1-3 in our facility. Videofluoroscopic swallow studies (type 1 alone), chest CT scans, and clinical data were collected.

resultsThirty-six children were included (n = 9 type 1, n = 14 type 2, and n = 13 type 3; age range 0.3-15.4 years). Abnormal swallowing characteristics were demonstrated in all children with type 1 (n = 8; 100%). Bronchiectasis was found on chest CT: 3 of 9 (33.3%), 2 of 14 (14.3%), and 2 of 13 (15.4%) of type 1, 2, and 3, respectively. Atelectasis, mucus plugging, bronchial wall thickening, and parenchymal changes were common. DISCUSSION: Swallow impairments were universal in children with type 1. Bronchiectasis was common in all pediatric SMA types, with a prevalence of 1 in 5. Routine monitoring and management of dysphagia/recurrent respiratory infection should be implemented for improvement in lung health.

Indexed as

BronchiectasisDeglutition DisordersLung DiseasesSpinal Muscular Atrophies of ChildhoodChildChild, PreschoolCross-Sectional StudiesFemaleHumansInfantInfant, NewbornMalePulmonary Atelectasis

Identifiers

PMID36657991
PMCPMC10186222
OpenAlexW4317469188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.